Raine Astin-Chamberlain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Raine Astin-Chamberlain has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ben Bloom
Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London , London
2 shared publications - Jason Pott
Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London; London, E1 2AT, UK
2 shared publications - Carlo L. Rosen
Department of Emergency Medicine, Beth Israel Deaconess Medical Center Harvard Medical School Boston Massachusetts USA
1 shared publication - Christie Lea Fritz
Department of Emergency Medicine, Beth Israel Deaconess Medical Center & Harvard Medical School, Boston, MA
1 shared publication - Elaine Cole
Centre for Trauma Sciences, Blizard Institute, Queen Mary University of London, London, UK
1 shared publication - Imogen Skene
Barts Health NHS Trust, London, UK
1 shared publication
Latest Publications
- Open Access
- 8 July 2026
- Published by Wiley in Emergency Medicine International
- Vol. 2026 (1) , 3925923
Does Early Opioid Use for Relief of Acute Abdominal Pain Increase Use of Abdominal CT or Prolong Emergency Department Length of Stay?
Opioid use is common for emergency department (ED) patients presenting with undifferentiated abdominal pain (AbdPain). Whether the potential analgesic benefits of opioids are offset by prolonged ED length of stay (LOS)—possibly due to extended evaluations or increased diagnostic testing—remains unclear. The primary objective was to determine whether administration of an opioid, compared to a nonopioid drug, as initial analgesia in AbdPain patients is associated with longer ED LOS after adjusting for demographics and pain severity. Secondary objectives evaluated whether initial opioid use was associated with higher adjusted likelihood of ordering abdominal CT (CTabd) or white blood cell count (WBC) testing. This retrospective observational study analyzed 4 months of electronic health record data from a single UK health system, including consecutive adult ED patients presenting with AbdPain who received analgesia and had a documented pain score. Variables included demographic factors, initial pain level, and analgesic administered. ED workup variables included diagnostic testing (CTabd, WBC), LOS, and disposition. Categorical data were summarized as proportions with binomial exact 95% confidence intervals (CIs); continuous data were summarized with medians and interquartile ranges (IQRs). Univariable analyses used Wilcoxon rank‐sum or Pearson’s χ 2 tests. Multivariable analyses employed quantile median regression for LOS and logistic regression for secondary outcomes. During the study period, there were 884 patients meeting eligibility criteria. The median ED LOS was 7.7 h (IQR 5.0 to 11.9). CTabd and WBC were ordered in 362 (41.0%) and 797 (90.2%) of cases. Univariable analysis showed no association between initial opioid use and ED LOS (p = 0.255), CTabd ordering (p = 0.404), or WBC testing (p = 0.820). Multivariable modeling adjusting for operational factors, demographics, and pain score confirmed no significant association between initial opioid use and ED LOS (coefficient 0.18, 95% CI: −0.71–1.08, p = 0.684), CTabd (OR 1.12, 95% CI: 0.84–1.50, p = 0.430), or WBC testing (OR 0.91, 95% CI: 0.58–1.43, p = 0.698). Among ED patients with abdominal pain, initial opioid administration was not associated with longer LOS or increased use of diagnostic testing.
- 8 July 2026
- Published by Wiley in Emergency Medicine International
- Vol. 2026 (1) , 3925923
Open AccessDoes Early Opioid Use for Relief of Acute Abdominal Pain Increase Use of Abdominal CT or Prolong Emergency Department Length of Stay?
Opioid use is common for emergency department (ED) patients presenting with undifferentiated abdominal pain (AbdPain). Whether the potential analgesic benefits of opioids are offset by prolonged ED length of stay (LOS)—possibly due to extended evaluations or increased diagnostic testing—remains unclear. The primary objective was to determine whether administration of an opioid, compared to a nonopioid drug, as initial analgesia in AbdPain patients is associated with longer ED LOS after adjusting for demographics and pain severity. Secondary objectives evaluated whether initial opioid use was associated with higher adjusted likelihood of ordering abdominal CT (CTabd) or white blood cell count (WBC) testing. This retrospective observational study analyzed 4 months of electronic health record data from a single UK health system, including consecutive adult ED patients presenting with AbdPain who received analgesia and had a documented pain score. Variables included demographic factors, initial pain level, and analgesic administered. ED workup variables included diagnostic testing (CTabd, WBC), LOS, and disposition. Categorical data were summarized as proportions with binomial exact 95% confidence intervals (CIs); continuous data were summarized with medians and interquartile ranges (IQRs). Univariable analyses used Wilcoxon rank‐sum or Pearson’s χ 2 tests. Multivariable analyses employed quantile median regression for LOS and logistic regression for secondary outcomes. During the study period, there were 884 patients meeting eligibility criteria. The median ED LOS was 7.7 h (IQR 5.0 to 11.9). CTabd and WBC were ordered in 362 (41.0%) and 797 (90.2%) of cases. Univariable analysis showed no association between initial opioid use and ED LOS (p = 0.255), CTabd ordering (p = 0.404), or WBC testing (p = 0.820). Multivariable modeling adjusting for operational factors, demographics, and pain score confirmed no significant association between initial opioid use and ED LOS (coefficient 0.18, 95% CI: −0.71–1.08, p = 0.684), CTabd (OR 1.12, 95% CI: 0.84–1.50, p = 0.430), or WBC testing (OR 0.91, 95% CI: 0.58–1.43, p = 0.698). Among ED patients with abdominal pain, initial opioid administration was not associated with longer LOS or increased use of diagnostic testing.
- 11 September 2024
- Published by BMJ in Emergency Medicine Journal
- Vol. 42 (2) , 82-90
Sex and gender reporting in UK emergency medicine trials from 2010 to 2023: a systematic review
Background Female participants are underrepresented in randomised control trials conducted in urgent care settings. Although sex and gender are frequently reported within demographic data, it is less common for primary outcomes to be disaggregated by sex or gender. The aim of this review is to report sex and gender of participants in the primary papers published on research listed on the National Institute of Health and Care Research (NIHR) Trauma and Emergency Care (TEC) portfolio and how these data are presented. Methods This is a systematic review of the published outputs of interventional trials conducted in UK EDs. Interventional trials were eligible to be included in the review if they were registered on the NIHR TEC research portfolio from January 2010, if the primary paper was published before 31 December 2023 and if the research was delivered primarily in the ED. Trials were identified through the NIHR open data platform and the primary papers were identified through specific searches using MedLine, EMBASE and PubMed. The primary objective of the review is to quantify the proportion of sex-disaggregated or gender-disaggregated primary outcomes in clinical trials within UK emergency medicine. Results The initial search revealed 169 registered research projects on the NIHR TEC portfolio during the study period, of which 24 met the inclusion criteria. Overall, 76 719 participants were included, of which 31 374 (40%) were female. Only one trial (CRYOSTAT-2) reported a sex-disaggregated analysis of the effect of the intervention on either primary or secondary outcomes, and no sex-based difference in treatment effect was detected. Conclusions Fewer females than males were included in TEC trials from 2010 to 2023. One trial reported the primary outcome stratified by sex. There is significant scope to increase the scientific value of TEC trials to females by funders.
- 11 September 2024
- Published by BMJ in Emergency Medicine Journal
- Vol. 42 (2) , 82-90
Sex and gender reporting in UK emergency medicine trials from 2010 to 2023: a systematic review
Background Female participants are underrepresented in randomised control trials conducted in urgent care settings. Although sex and gender are frequently reported within demographic data, it is less common for primary outcomes to be disaggregated by sex or gender. The aim of this review is to report sex and gender of participants in the primary papers published on research listed on the National Institute of Health and Care Research (NIHR) Trauma and Emergency Care (TEC) portfolio and how these data are presented. Methods This is a systematic review of the published outputs of interventional trials conducted in UK EDs. Interventional trials were eligible to be included in the review if they were registered on the NIHR TEC research portfolio from January 2010, if the primary paper was published before 31 December 2023 and if the research was delivered primarily in the ED. Trials were identified through the NIHR open data platform and the primary papers were identified through specific searches using MedLine, EMBASE and PubMed. The primary objective of the review is to quantify the proportion of sex-disaggregated or gender-disaggregated primary outcomes in clinical trials within UK emergency medicine. Results The initial search revealed 169 registered research projects on the NIHR TEC portfolio during the study period, of which 24 met the inclusion criteria. Overall, 76 719 participants were included, of which 31 374 (40%) were female. Only one trial (CRYOSTAT-2) reported a sex-disaggregated analysis of the effect of the intervention on either primary or secondary outcomes, and no sex-based difference in treatment effect was detected. Conclusions Fewer females than males were included in TEC trials from 2010 to 2023. One trial reported the primary outcome stratified by sex. There is significant scope to increase the scientific value of TEC trials to females by funders.